Johnson & Johnson Medtech, Qure.ai partner to enhance early detection of lung cancer in India

"By harnessing of artificial intelligence in the modalities of X-Ray & CT scans, Johnson & Johnson MedTech India & Qure.ai are enabling the detection of potential lung nodules that might otherwise be missed. This happens through flagging risky nodules in X-Rays and CT Scans that can potentially turn out to be malignant. It also introduces the concept of structured IPN clinics where there is a proactive impetus towards incidental screening of early-stage lung cancer. This partnership embodies Johnson & Johnson MedTech’s commitment to enhancing early lung cancer detection, ultimately transforming the standard of lung cancer care," the release stated.

Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, “Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.”